ChanTest provides safety testing and discovery services to help biopharmaceutical companies achieve their goals.The accuracy and repeatability of results from ChanTest's assays has been validated through participation in numerous blinded studies, including the recently concluded study by ILSI. PDF

ION CHANNEL SCREENING ASSAYS
Identify the risk of hERG inhibition and QT prolongation early in the drug development process.

ION CHANNEL CONCENTRATION-RESPONSE ASSAYS
Determine theraputic doses and safety margins to assess a drug's potential to inpair cardiac repolarization.

REPOLARIZATION ASSAYS
Reveal the presence of mixed ion channel effects and determine the effects of drugs on cardiac action potential and QT interval.

DOSE SOLUTION ANALYSIS (DSA)
Verify applied concentrations with analytical sample testing of dose solutions.

CONSULTATIONS
ChanTest has the experience and capabilities to assist with regulatory issues related to non-clinical cardiac safety testing and has helped clients prepare for IND interviews at the FDA. Please contact: Dr. Arthur M. "Buzz" Brown.